CO-ACETAMOL 500mg + 30mg Price

Overview

Welcome to Dwaey, specifically on CO-ACETAMOL 500mg + 30mg page.
This medicine contains an important and useful components, as it consists of
Codeine Phosphate / Paracetamolis available in the market in concentration

Name

Daclatasvir

Precaution

Before starting **Daclatasvir**, it is essential for patients to consult their healthcare provider to ensure the medication is appropriate for their specific condition. Key precautions include: - **Liver Disease**: **Daclatasvir** is primarily used for treating **hepatitis C**. It should be used cautiously in patients with **severe liver disease** (cirrhosis), as they may experience more severe side effects or require dose adjustments. - **Pregnancy and Breastfeeding**: **Daclatasvir** should be used with caution during pregnancy and only if the benefits outweigh the potential risks. Its safety during breastfeeding is not well-established, so consult a healthcare provider if breastfeeding. - **Drug Interactions**: **Daclatasvir** can interact with other medications, so a thorough review of a patient's current medications is necessary to avoid potentially harmful interactions. It is important to avoid certain **anticonvulsants**, **antifungals**, and **antibiotics**. - **Renal Impairment**: While **Daclatasvir** is not eliminated significantly through the kidneys, it should still be used cautiously in patients with severe renal impairment, as dosage adjustments may be necessary for concomitant use with other drugs. - **HCV Genotype and Resistance**: The efficacy of **Daclatasvir** may be influenced by the **HCV genotype** and any existing **drug resistance mutations**. The medication should be used in combination with other antiviral drugs as part of a prescribed regimen to maximize efficacy.

Indication

**Daclatasvir** is primarily indicated for the treatment of **chronic hepatitis C virus (HCV)** infection. It is a direct-acting antiviral (DAA) agent that is used in combination with other antiviral medications like **sofosbuvir**, **ribavirin**, or **peginterferon** to treat **HCV genotype 1**, **genotype 2**, **genotype 3**, and **genotype 4** infections. It is used to reduce the viral load of HCV, improve liver function, and prevent complications such as **cirrhosis**, **liver failure**, and **liver cancer**. **Daclatasvir** helps inhibit the replication of the virus by targeting the **NS5A** protein, which is crucial for the viral lifecycle.

Contra indication

**Daclatasvir** is contraindicated in the following situations: - **Hypersensitivity**: Any known **allergy** or **hypersensitivity** to **Daclatasvir** or any of its components. - **Severe Hepatic Impairment**: The use of **Daclatasvir** is contraindicated in patients with **Child-Pugh class C** (severe hepatic impairment), as the drug can exacerbate liver dysfunction. - **Co-administration with Strong CYP3A Inhibitors or Inducers**: **Daclatasvir** should not be used in combination with drugs that are strong **CYP3A inhibitors** (e.g., **ketoconazole**, **ritonavir**) or **CYP3A inducers** (e.g., **rifampin**, **carbamazepine**) because these can affect the metabolism of **Daclatasvir** and either reduce its effectiveness or increase the risk of side effects.

Side Effect

Common and severe side effects of **Daclatasvir** include: - **Fatigue**: Patients may experience **fatigue** or general malaise, especially during the first few weeks of treatment. - **Headache**: A common side effect of **Daclatasvir** is **headache**, which may be mild to moderate in severity. - **Nausea**: **Daclatasvir** may cause **nausea**, particularly when taken in combination with other medications like **sofosbuvir** or **ribavirin**. - **Diarrhea**: Gastrointestinal symptoms such as **diarrhea** or **abdominal pain** can occur during treatment. - **Insomnia**: Some patients may experience **difficulty sleeping** or **insomnia** while on **Daclatasvir**. - **Liver Enzyme Elevations**: In some cases, **liver enzymes** (e.g., **ALT**, **AST**) may be elevated during treatment, especially when used in combination with **ribavirin** or other antivirals. These elevations should be monitored to prevent liver damage. - **Rash**: In rare cases, **rash** or **skin reactions** may occur, which may require discontinuation of the medication if severe. - **Anemia**: If combined with **ribavirin**, **anemia** (low red blood cell count) can occur, requiring close monitoring of blood counts.

Pregnancy Category ID

0

Mode of Action

**Daclatasvir** is an **NS5A inhibitor** and works by inhibiting the **NS5A protein**, which is essential for the replication of the **hepatitis C virus (HCV)**. The NS5A protein plays a critical role in the replication and assembly of the virus. By inhibiting this protein, **Daclatasvir** prevents the virus from multiplying and spreading to other cells, ultimately reducing the viral load in the body. When used in combination with other antiviral drugs like **sofosbuvir** (which inhibits the **NS5B** polymerase), it can significantly improve treatment outcomes by blocking multiple steps in the viral replication cycle.

Interaction

**Daclatasvir** can interact with a range of medications, leading to altered efficacy or potential toxicity. Key interactions include: - **CYP3A4 Inhibitors**: Strong **CYP3A4 inhibitors**, such as **ritonavir**, **ketoconazole**, and **clarithromycin**, can increase the concentration of **Daclatasvir**, which may lead to toxicity. - **CYP3A4 Inducers**: Drugs that induce **CYP3A4**, such as **rifampin**, **carbamazepine**, **phenytoin**, and **St. John’s Wort**, can reduce the effectiveness of **Daclatasvir** by increasing its metabolism. - **Anticonvulsants**: Drugs like **phenytoin** and **carbamazepine** can decrease the effectiveness of **Daclatasvir** and should be avoided or closely monitored if used concurrently. - **Antifungal Agents**: **Itraconazole** and other **azole antifungals** can increase **Daclatasvir** blood concentrations, increasing the risk of side effects. - **Other Direct-Acting Antivirals (DAAs)**: Careful consideration and monitoring are necessary when using **Daclatasvir** in combination with other **DAAs**, as some regimens may require dose adjustments to reduce the risk of overlapping side effects or suboptimal efficacy. - **Rifampin**: **Rifampin**, a potent **CYP3A4 inducer**, can significantly reduce the concentration of **Daclatasvir** in the blood, rendering it less effective.

Pregnancy Category Note

Information not available

Adult Dose

The recommended adult dose of **Daclatasvir** for the treatment of **hepatitis C** is typically **60 mg** once daily, in combination with **sofosbuvir** or **ribavirin**, depending on the genotype of the virus. Treatment duration usually lasts between **12 to 24 weeks**, depending on the specific regimen and the patient's individual response to therapy. If used in combination with **ribavirin**, the dose of **ribavirin** should be adjusted based on the patient's weight.

Child Dose

**Daclatasvir** is not approved for use in **pediatric patients** (under 18 years of age), as its safety and efficacy have not been established in this population. Therefore, it is generally not recommended for children and adolescents with **hepatitis C**. Treatment in pediatric populations should be guided by other approved regimens.

Renal Dose

**Daclatasvir** is not significantly cleared by the kidneys, so dose adjustments are not typically required in patients with **renal impairment**. However, when used in combination with other medications, such as **sofosbuvir**, which may require renal dose adjustments, it is important to assess the patient's renal function regularly and adjust the treatment regimen as necessary.

Administration

Information not available